04:45 PM EST - Oncolytics Biotech Inc : Announced that the U.S. Food and Drug Administration has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal who have progressed on or were intolerant to one or more prior lines of systemic therapy. Oncolytics Biotech Inc
shares N.ONCY are trading unchanged at $0.85.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=4840043768112307
